Core Insights - On December 19, a total of 10 companies announced 11 stock repurchase updates, indicating a significant activity in the market [1] - One company disclosed a stock repurchase plan for the first time, while another company's repurchase plan was approved by the shareholders' meeting [1] - Five companies have completed their repurchase plans, showcasing a trend of companies returning capital to shareholders [1] Group 1: Stock Repurchase Plans - One company announced a stock repurchase plan exceeding 10 million yuan, with Tibet Pharmaceutical having the highest proposed repurchase amount of up to 200 million yuan [1] - Anke Bio's repurchase plan was approved with the highest amounts proposed at 4.8558 million yuan and 1.3771 million yuan [1] Group 2: Implementation Progress - The companies with the highest repurchase amounts in progress are Lige Energy, Yirui Technology, and Sanlisi, with repurchases of 161 million yuan, 8.0786 million yuan, and 4.914 million yuan respectively [1] Group 3: Completed Repurchases - Five companies completed repurchases exceeding 10 million yuan, with the highest amounts from Atas, Jihua Group, and Nanjing Pharmaceutical at 501 million yuan, 100 million yuan, and 88.9221 million yuan respectively [1] - As of December 19, a total of 1,966 repurchase plans have been implemented this year, involving 1,424 companies, with 386 companies completing repurchases exceeding 100 million yuan [1] - The companies with the highest completed repurchase amounts include Midea Group, Kweichow Moutai, and Muyuan Foods, with completed repurchases of 10.035 billion yuan, 6 billion yuan, and 3.001 billion yuan respectively [1]

Core Viewpoint - Zhao Yeqing, the actual controller and chairman of Jincheng Pharmaceutical, was fined 1.5 million yuan by the Securities Regulatory Commission for manipulating the company's stock and received a four-year market ban [1] Group 1: Company Actions and Consequences - Zhao Yeqing resigned from his positions as chairman, director, and committee member of the board due to personal reasons on the same day he was penalized [1] - The manipulation led to a loss of 7.39 million yuan for Zhao, raising questions about how a chairman could incur losses while having insider information [1][3] - Zhao's stock manipulation occurred from August 18, 2017, to February 10, 2020, during a period when the stock market was generally declining, with the Shanghai Composite Index dropping from 3268.72 to 2890.49, a decrease of 11.57% [3] Group 2: Performance and Market Conditions - Jincheng Pharmaceutical's financial performance did not support Zhao's stock manipulation efforts, with revenue growth declining significantly in 2018 and 2019, and a notable drop in net profit [4] - The company's revenue in 2017 grew by 96.29%, but by 2019, revenue had decreased by 7.09%, and net profit attributable to shareholders fell by 74.25% [4] - Zhao's highest shareholding was only 9.04% of the circulating stock, which is below the typical control threshold of 30% needed to effectively manipulate stock prices [5] Group 3: Implications for Investors - The incident highlights the lack of profitability in the A-share market, as even a chairman with significant advantages lost money, indicating challenges for ordinary investors [3] - Zhao's actions serve as a cautionary tale for corporate leaders, emphasizing the importance of ethical conduct and the potential consequences of illegal activities [5]

证券之星消息，截至2025年12月18日收盘，中 关 村(000931)报收于4.9元，上涨1.45%，换手率0.91%， 成交量6.83万手，成交额3339.55万元。 12月18日的资金流向数据方面，主力资金净流入229.32万元，占总成交额6.87%，游资资金净流出 559.72万元，占总成交额16.76%，散户资金净流入330.4万元，占总成交额9.89%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-18 | 4.90 | 1.45% | 229.32万 | 6.87% | -559.72万 | -16.76% | 330.40万 | 9.89% | | 2025-12-17 | | 4.83 0.63% | ● 416.18万 | 10.53% | -241.37万 | -6.11% | -174.81万 | -4.42% | | 2025-12-16 | | 4 ...

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

毕得医药12月18日大宗交易平台共发生3笔成交，合计成交量16.74万股，成交金额1004.40万元。成交价 格均为60.00元，相对今日收盘价折价7.25%。从参与大宗交易营业部来看，机构专用席位共出现在1笔 成交的买方或卖方营业部中，合计成交金额为204.00万元，净买入204.00万元。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。 两融数据显示，该股最新融资余额为2869.09万元，近5日减少268.76万元，降幅为8.57%。 据天眼查APP显示，上海毕得医药科技股份有限公司成立于2007年04月27日，注册资本9088.2948万人 民币。（数据宝） 12月18日毕得医药大宗交易一览 | 成交量 （万 | 成交金额 | 成交价 格 | 相对当日收盘 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 股） | （万元） | （元） | 折溢价（%） | | | | 10.00 | 600.00 | 60.00 | -7.25 | 广发证券股份有限公司总部 | 浙商证券股份有限公司上 | | | ...

证券日报网讯 12月18日晚间，海思科（002653）发布公告称，公司于2025年12月18日收到政府补助 12000万元。 ...

海思科公告，公司于2025年12月18日收到深圳证券交易所上市审核中心出具的《关于海思科医药集团股 份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所上市审核中心对公司提交的向特 定对象发行股票的申请文件进行了审核，认为公司符合发行条件、上市条件和信息披露要求。公司本次 向特定对象发行股票的事宜尚需获得中国证监会同意注册的批复后方可实施。 ...

毕得医药公告，公司股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹于2025年9月18日至2025 年12月17日期间合计减持公司股份437,902股，占公司总股本的0.48%。其中，李怡静减持91,673股，减 持价格区间为75.00元/股至82.00元/股，减持总金额为7,245,513元；陈俊减持136,395股，减持价格区间 为70.56元/股至77.80元/股，减持总金额为9,931,500元；李黎减持10,000股，减持价格区间为66.65元/股 至82.20元/股，减持总金额为796,133元；杜鹃减持56,500股，减持价格区间为72.00元/股至76.00元/股， 减持总金额为3,800,000元；李爱飞减持63,255股，减持价格区间为78.50元/股至82.00元/股，减持总金额 为4,991,075元；耿勇减持32,119股，减持价格区间为65.20元/股至81.12元/股，减持总金额为2,404,480 元；蒋亚妹减持47,960股，减持价格区间为77.04元/股至79.03元/股，减持总金额为3,747,171元。 ...

第3笔成交价格为60.00元，成交3.34万股，成交金额200.40万元，溢价率为-7.25%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营 业部。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。该股近5个交易日 累计下跌3.45%，主力资金合计净流出501.35万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月18日，毕得医药收跌1.57%，收盘价为64.69元，发生3笔大宗交易，合计成交量16.74万股，成交金 额1004.4万元。 第1笔成交价格为60.00元，成交10.00万股，成交金额600.00万元，溢价率为-7.25%，买方营业部为广发 证券股份有限公司总部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 第2笔成交价格为60.00元，成交3.40万股，成交金额204.00万元，溢价率为-7.25%，买方营业部为机构 专用，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 ...

Core Viewpoint - The company emphasizes its clear medium to long-term development plan, focusing on sustainable development driven by green and intelligent chemical technology innovation [1] Group 1: Development Strategy - The company's key tasks include advancing digitalization and intelligence in management systems [1] - Strengthening compliance systems and scaling up production capacity is a priority [1] - The company aims to accelerate the layout of new molecular businesses such as TIDES and XDC [1] Group 2: Market Adaptation - The company is adapting to changes in the international biopharmaceutical investment environment, which has led to fluctuations in downstream demand [1] - Investment pace has been prudently planned and dynamically adjusted based on market demand, capacity layout, and usage efficiency to maximize shareholder interests [1] - The company will continue to monitor environmental changes and make reasonable arrangements for the use of raised funds [1]